ClinicalTrials.gg
CompletedNCT06049017ANTHEM-UCUpdated Apr 13, 2026

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of JNJ-77242113 and Placebo in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Completed at 177 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
12th of 28
252 · median 205
Started
2023
the only one that year
Phase 2
5 of 43
none open now
Registered
30th of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 2, and was the 30th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form 18 years of age or older
  • Documented diagnosis of ulcerative colitis (UC) of at least 12 weeks prior to screening
  • Moderately to severely active UC as per the modified Mayo score
  • Demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Participants with current or prior diagnosis of fulminant colitis and/or toxic megacolon
  • UC limited to rectum only or to less than (\<) 15 centimeters (cm) of colon
  • Presence of a stoma
  • Presence or history of fistula
  • History of extensive colonic resection (example, \<30 cm of colon remaining)
  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or clinical findings suggestive of Crohn's disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Group 1: JNJ-77242113 Dose-1

    Participants will receive JNJ-77242113 Dose-1 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.

    Drug: JNJ-77242113

  • Experimental
    Group 2: JNJ-77242113 Dose-2

    Participants will receive JNJ-77242113 Dose-2 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.

    Drug: JNJ-77242113

  • Experimental
    Group 3: JNJ-77242113 Dose-3

    Participants will receive JNJ-77242113 Dose-3 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.

    Drug: JNJ-77242113

  • Experimental
    Group 4: Placebo

    Participants will receive placebo tablets orally from Week 0 through Week 28. Placebo-treated participants who meet the criteria of inadequate response at Week 16, will receive JNJ-77242113 Dose-3 tablet orally through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention, will continue in the 48-week LTE period and receive the same treatment up to Week 76.

    Drug: JNJ-77242113 · Drug: Placebo

Interventions

  • JNJ-77242113 tablet will be administered orally.

  • DrugPlacebo

    Placebo tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Response at Week 12

    Clinical response is defined as decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants with Clinical Remission at Week 12

    Clinical remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: Week 12

  2. Percentage of Participants with Symptomatic Remission at Week 12

    Symptomatic remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, and a rectal bleeding subscore of 0.

    Time frame: Week 12

  3. Percentage of Participants with Endoscopic Improvement at Week 12

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: Week 12

  4. Percentage of Participants with Histologic-endoscopic Mucosal Improvement at Week 12

    Histologic-endoscopic mucosal improvement is defined as a combination of histologic remission and endoscopic improvement. Histologic remission and endoscopic improvement are based on the histologic grading and the Mayo endoscopy subscore.

    Time frame: Week 12

  5. Percentage of Participants with Adverse Events (AE) and Serious Adverse Evets (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

    Time frame: Up to Week 76

07

Study locations

177 sites
  • Clinnova Research
    Anaheim, California 92805, United States
  • Hoag Memorial Hospital
    Newport Beach, California 92663, United States
  • Medical Associates Research Group, Inc.
    San Diego, California 92123, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • I.H.S. Health. LLC
    Kissimmee, Florida 34741, United States
  • Endoscopic Research Inc
    Orlando, Florida 32803-1853, United States
  • GCP Clinical Research
    Tampa, Florida 33609, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Gastroenterology of Southern Indiana
    New Albany, Indiana 47150, United States
  • Cotton O'Neil Digestive Health Center
    Topeka, Kansas 66606, United States
  • Ochsner Medical Center
    Jefferson, Louisiana 70121, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202-2102, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • New York Gastroenterology Associates
    New York, New York 10075, United States
  • DiGiovanna Institute for Medical Education & Research
    North Massapequa, New York 11758, United States
  • UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Atrium Health
    Charlotte, North Carolina 28204, United States
  • Charlotte Gastroenterology and Hepatology, PLLC
    Charlotte, North Carolina 28207, United States
  • Northshore Gastroenterology Research, LLC
    Westlake, Ohio 44145, United States
  • Digestive Disease Specialists Inc
    Oklahoma City, Oklahoma 73112, United States
  • Gastroenterology Associates P.A.
    Greenville, South Carolina 29607, United States
  • DHAT Research Institute
    Garland, Texas 75044, United States
  • Amel Med LLC Research
    Georgetown, Texas 78628, United States
  • Accurate Clinical Research, Inc.
    Humble, Texas 77346, United States
  • Caprock Gastro Research
    Lubbock, Texas 79424, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Care Access Research, Ogden
    Ogden, Utah 84403, United States
  • Gastroenterology Associates of Tidewater
    Chesapeake, Virginia 23320, United States
  • Washington Gastroenterology, PLLC
    Bellevue, Washington 98004, United States
  • Washington Gastroenterology, PLLC 1
    Tacoma, Washington 98405, United States
  • Cer Instituto Medico
    Buenos Aires, B1878DVB, Argentina
  • CIPREC
    Buenos Aires, C1061AAS, Argentina
  • Gedyt - Consultorios Gastroenterologia
    Buenos Aires, C1425, Argentina
  • Hospital Provincial del Centenario
    Rosario, S2000KDS, Argentina
  • Sanatorio 9 de Julio
    San Miguel de Tucumán, 4000, Argentina
  • Sunshine Coast University Hospital
    Birtinya, 4575, Australia
  • Blacktown Hospital
    Blacktown, 2148, Australia
  • Concord Repatriation General Hospital
    Concord, 2139, Australia
  • Wollongong Private Hospital
    Wollongong, 2500, Australia
  • CHU Saint-Pierre
    Brussels, 1000, Belgium
  • AZ Sint-Lucas
    Ghent, 9000, Belgium
  • Ghent University Hospital
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
    Liège, 4000, Belgium
  • Vitaz
    Sint-Niklaas, 9100, Belgium
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, 18618-687, Brazil
  • L2IP Instituto de Pesquisas Clinicas
    Brasília, 70.200-730, Brazil
  • CDC - Centro Digestivo de Curitiba
    Curitiba, 80430-180, Brazil
  • Hospital de Clinicas de Porto Alegre - Hospital de Clinicas
    Porto Alegre, 90035 903, Brazil
  • Pesquisare Saude
    Santo André, 09080-110, Brazil
  • BR TRIALS Ensaios Clinicos e Consultoria Ltda
    São Paulo, 01236030, Brazil
  • Instituto D Or de Pesquisa e Ensino
    São Paulo, 01401 002, Brazil
  • INTEGRAL Pesquisa e Ensino
    Votuporanga, 15501-405, Brazil
  • Gastroenterology and Internal Medicine Research Institute (GIRI)
    Edmonton, Alberta T5R 1W2, Canada
  • Barrie GI Associates
    Barrie, Ontario L4M 7G1, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • ABP Research Services Corp.
    Oakville, Ontario L6L 5L7, Canada
  • Centre Hospitalier de l'Universite de Montreal
    Montreal, Quebec H2X 0C1, Canada
  • The second Xiangya Hospital of Central South University
    Changsha, 410011, China
  • Chongqing General Hospital
    Chongqing, 400014, China
  • The First Affiliated Hospital Sun Yat sen University
    Guangzhou, 510060, China
  • The Sixth Affiliated Hospital Sun Yat sen University
    Guangzhou, 510655, China
  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
    Hangzhou, 310000, China
  • Qilu Hospital of Shandong University
    Jinan, 250012, China
  • Lanzhou University Second Hospital
    Lanzhou, 730031, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • Shengjing Hospital Of China Medical University
    Shenyang, 110022, China
  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, 430022, China
  • Wuxi People s Hospital
    Wuxi, 214023, China
  • The Second Affiliated Hospital of Air Force Medical University - Tangdu Hospital
    Xi'an, 710038, China
  • Nemocnice Ceske Budejovice
    České Budějovice, 370 01, Czechia
  • Gastroenterologie, s.r.o., Hradec Kralove
    Hradec Kralova, 500 02, Czechia
  • Hepato-gastroenterologie HK, s.r.o.
    Hradec Králové, 500 12, Czechia
  • ISCARE a.s.
    Prague, 19000, Czechia
  • Nemocnice Slany
    Slaný, 27401, Czechia
  • CHRU Besancon Hopital Jean Minjoz
    Besançon, 25030, France
  • APHP - Hopital Henri Mondor
    Créteil, 94000, France
  • CHRU de Lille Hopital Claude Huriez
    Lille, 59037, France
  • Clinique Ambroise Pare
    Neuilly-sur-Seine, 92200, France
  • CHU de Nice Hopital de l Archet
    Nice, 06202, France
  • CHU Nimes Hopital Caremeau
    Nîmes, 30900, France
  • APHP - Hopital Bichat - Claude Bernard
    Paris, 75018, France
  • Hospices Civils de Lyon CHU Lyon Sud
    Pierre-Bénite, 69495, France
  • CHU Saint Etienne Hopital Nord
    Saint-Priest-en-Jarez, 42270, France
  • CHU Toulouse - Hopital de Rangueil
    Toulouse, 31400, France
  • CHU de Nancy_ Hopital Brabois
    Vandœuvre-lès-Nancy, 54500, France
  • Klinikum Augsburg
    Augsburg, D-86158, Germany
  • Krankenhaus Waldfriede Mitte
    Berlin, 14163, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 01307, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Universitatsklinikum Schleswig Holstein Kiel
    Kiel, 24105, Germany
  • Eugastro GmbH
    Leipzig, 04103, Germany
  • Staedtisches Klinikum Lueneburg
    Lüneburg, 21339, Germany
  • Gastroenterologische Gemeinschaftspraxis Minden
    Minden, 32423, Germany
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Semmelweis Egyetem 1
    Budapest, 1088, Hungary
  • Pannónia Magánorvosi Centrum Kft
    Budapest, H-1136, Hungary
  • Vasutegeszsegugyi Nonprofit Kozhasznu Kft
    Debrecen, 4025, Hungary

Showing the first 100 of 177 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2024, 11 months.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 11 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 21, 2023
StartActual
Oct 9, 2023
Primary completionActual
Sep 26, 2024
CompletionActual
Jan 5, 2026
Results delay requested
Sep 25, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049017
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 9, 2023
Primary completion
Sep 26, 2024
Completion
Jan 5, 2026
Last update
Apr 13, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icotrokinra

Start the discussion